title: [Ximedone in the treatment of patients with burns].
abstract: The authors studied xymedone, a new medicamentous agent from the group of pyrimidine derivatives. It was prescribed per os, 0.5 g taken three times daily. The experimental group consisted of 52 patients with IIIA and B degree thermal burns covering an area of 10 to 40%. The comparative appraisal was conducted with patients (60) treated by a complex of measures including methyluracil. Analysis of the obtained data showed a statistically significant, as compared to the controls, more rapid restoration of the peripheral blood parameters, decrease of C-reactive protein and level of sialic acid, and increase of total protein content and its gamma globulin fraction. Xymedone contributed to correction of blood dysproteinemia and produced an active effect on nucleic acid metabolism; the level of nucleic acids in the cells of the granulation tissue was much higher in the experimental group after treatment than in the controls. The normal ratio of T- and B-lymphocytes was restored and the phagocytosis indices grew. The production of coagulation and anticoagulation factors became normal, which coincided with cleaning of the granulations from fibrinous deposits and disappearance of the pathological predisposition to bleeding and easy damage of the granulation tissue. Under the effect of the agent the patients' appetite improved, the duration of the dehydration phase reduced, the rate of growth of microgranular granulations and epithelium increased, and the incidence of keloid cicatrices decreased. No unfavorable side effects of the agent were encountered. Xymedone is recommended for wide use in medical practice.
authors.forename: I Z
authors.initials: IZ
authors.lastname: Shafikov
authors.forename: G A
authors.initials: GA
authors.lastname: Izmaĭlov
authors.forename: S G
authors.initials: SG
authors.lastname: Izmaĭlov
authors.forename: S M
authors.initials: SM
authors.lastname: Gorbunov
authors.forename: L Kh
authors.initials: LKh
authors.lastname: Mavziutov
authors.forename: R A
authors.initials: RA
authors.lastname: Abdulkhakov
authors.forename: G B
authors.initials: GB
authors.lastname: Evranova
authors.forename: S A
authors.initials: SA
authors.lastname: Usmanova
authors.forename: T F
authors.initials: TF
authors.lastname: Rakhmatullina-Miller
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects; D001798:Blood Proteins / Q000187:drug effects; D002056:Burns / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D002097:C-Reactive Protein / Q000187:drug effects; D006097:Granulation Tissue / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D019158:N-Acetylneuraminic Acid; D010587:Phagocytosis / Q000187:drug effects; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D012794:Sialic Acids / Q000097:blood; D013601:T-Lymphocytes / Q000187:drug effects; D014498:Uracil / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects
chemical_list: D000897:Anti-Ulcer Agents; D001798:Blood Proteins; D011743:Pyrimidines; D012794:Sialic Acids; C069705:xymedon; D014498:Uracil; C008378:6-methyluracil; D002097:C-Reactive Protein; D019158:N-Acetylneuraminic Acid
vernacular_title: Primenenie ksimedona v lechenii obozhzhennykh.